Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum
Open accessPublished version of a preprint
The DOI matches its Crossref record; 73 of the 79 references it cites were found in a registry or an index; 36 of the 58 sources its claims cite were checked for support.
Abstract
The clinical syndromes of frontotemporal dementia are clinically and neuropathologically heterogeneous, but processes such as neuroinflammation may be common across the disease spectrum. We investigated how neuroinflammation relates to the localization of tau and TDP-43 pathology, and to the heterogeneity of clinical disease. We used PET in vivo with (i) 11C-PK-11195, a marker of activated microglia and a proxy index of neuroinflammation; and (ii) 18F-AV-1451, a radioligand with increased binding to pathologically affected regions in tauopathies and TDP-43-related disease, and which is used as a surrogate marker of non-amyloid-β protein aggregation. We assessed 31 patients with frontotemporal dementia (10 with behavioural variant, 11 with the semantic variant and 10 with the non-fluent variant), 28 of whom underwent both 18F-AV-1451 and 11C-PK-11195 PET, and matched control subjects (14 for 18F-AV-1451 and 15 for 11C-PK-11195). We used a univariate region of interest analysis, a paired correlation analysis of the regional relationship between binding distributions of the two ligands, a principal component analysis of the spatial distributions of binding, and a multivariate analysis of the distribution of binding that explicitly controls for individual differences in ligand affinity for TDP-43 and different tau isoforms. We found significant group-wise differences in 11C-PK-11195 binding between each patient group and controls in frontotemporal regions, in both a regions-of-interest analysis and in the comparison of principal spatial components of binding. 18F-AV-1451 binding was increased in semantic variant primary progressive aphasia compared to controls in the temporal regions, and both semantic variant primary progressive aphasia and behavioural variant frontotemporal dementia differed from controls in the expression of principal spatial components of binding, across temporal and frontotemporal cortex, respectively. There was a strong positive correlation between 11C-PK-11195 and 18F-AV-1451 uptake in all disease groups, across widespread cortical regions. We confirmed this association with post-mortem quantification in 12 brains, demonstrating strong associations between the regional densities of microglia and neuropathology in FTLD-TDP (A), FTLD-TDP (C), and FTLD-Pick's. This was driven by amoeboid (activated) microglia, with no change in the density of ramified (sessile) microglia. The multivariate distribution of 11C-PK-11195 binding related better to clinical heterogeneity than did 18F-AV-1451: distinct spatial modes of neuroinflammation were associated with different frontotemporal dementia syndromes and supported accurate classification of participants. These in vivo findings indicate a close association between neuroinflammation and protein aggregation in frontotemporal dementia. The inflammatory component may be important in shaping the clinical and neuropathological patterns of the diverse clinical syndromes of frontotemporal dementia.
Overview
CoChat Summary
## TL;DR
This PET and post-mortem study found that neuroinflammation and protein aggregation co-localize across the frontotemporal dementia (FTD) spectrum, both regionally and across syndromes. The spatial pattern of neuroinflammation was disease-specific and classified FTD groups more accurately than protein-aggregation patterns.
## Key findings
- In regional PET analyses, 11C-PK-11195 and 18F-AV-1451 binding were significantly correlated within each group: svPPA r(81) = 0.727 before control subtraction and 0.883 after; bvFTD r(81) = 0.582 before and 0.499 after; nfvPPA r(81) = 0.427 before and 0.589 after, all P < 0.0001.
- Repeated-measures ANOVA showed significant region-by-diagnosis interactions for both tracers versus controls: 11C-PK-11195 F(37.4,423.5) = 3.54, P < 0.001 and 18F-AV-1451 F(33.6,403.6) = 3.80, P < 0.001.
- After FDR correction, elevated 11C-PK-11195 binding was seen in bvFTD in bilateral superior frontal gyri and putamen, right nucleus accumbens, left posterior orbital gyrus, inferior frontal gyrus and middle frontal gyrus; in svPPA it was elevated in multiple temporal and related regions, and in nfvPPA no regions survived FDR correction.
- Post-mortem immunohistochemistry showed a significant relationship between pathology density and microglia density [Wald χ2(1) = 21.40, P < 0.001], driven by amoeboid microglia [Wald χ2(1) = 30.83, P < 0.001] but not ramified microglia [Wald χ2(1) = 0.02, P = 0.898].
## Methods
- The study used the NIMROD cohort: 31 FTD patients (10 bvFTD, 11 svPPA, 10 nfvPPA) scanned with 18F-AV-1451; 28 of these also had 11C-PK-11195 PET. Control groups included 14 participants for 18F-AV-1451 and 15 different participants for 11C-PK-11195.
- PET data were analyzed across 83 regions of interest using repeated-measures ANOVA, regional correlations between tracers, principal component analysis, and non-parametric multi-dimensional scaling with 10-fold cross-validated linear SVM classification.
- Quantitative post-mortem immunohistochemistry was performed on 12 cases (3 FTLD-Pick’s, 3 FTLD-TDP type C, 3 FTLD-TDP type A, 3 Braak stage V Alzheimer’s disease) across four brain regions, with generalized linear models and correlations used to relate pathology to microglia.
## Limitations
- The paper states that the main limitation is small group size; although larger than most prior PET studies in FTD, each diagnostic group was still small, reducing power for group differences and clinical associations.
- The authors state that genotyping and amyloid testing were only done when clinically indicated and by consent, so not all participants had direct amyloid assessment or genotyping.
- Evident from the text: pathological subtype could not be determined in vivo, so the clinical diagnostic groups cannot be mapped cleanly onto specific proteinopathies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
24 Valid · 1 Not valid · 7 Not checked · 99 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, there are several different pathological proteins and aggregation morphologies in FTD, with generally weak correlations between clinical syndrome and the type of pathological protein (Seelaar et al., 2011)”
§ Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum > Introduction
What the sources say
- Partly supportedcites Seelaar et al., 2011 sourceExperimental — accuracy not yet measured
The Clinical Presentation section (page unavailable) says that associations between PPA syndromes and underlying pathology are “relatively strong,” though not absolute. The Future Directions section (page unavailable) indicates that distinguishing pathological subtypes of behavioural-variant FTD during life remains difficult. Thus, the review supports limited clinical prediction for some FTD presentations, but not the blanket characterization of correlations as generally weak. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In particular, there is converging evidence for the role of neuroinflammation in neurodegenerative dementias, including FTD, from genetic associations (Guerreiro et al., 2013; Rayaprolu et al., 2013; Broce et al., 2018), CSF (Sjogren et al., 2004; Woollacott et al., 2018), epidemiology (Miller et al., 2013, 2016), post-mortem tissue (Venneti et al., 2008; Lant et al., 2014) and animal models”
§ Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum > Introduction
What the sources say
- Supportedcites Guerreiro et al., 2013 source
The citation is attached to the genetic-associations part of the sentence, not to the CSF, epidemiology, tissue, or animal-model evidence. The Comment section (page unavailable) reports TREM2 mutations in three patients with dementia and describes TREM2 as an immune-response receptor expressed on microglia; the paper characterizes their presentation as FTD-like. (LLM, conf=0.90)
- Supportedcites Sjogren et al., 2004 source
The citation is offered as CSF-line evidence for neuroinflammation in neurodegenerative dementia including FTD, and our copy of Sjogren et al. (2004) is exactly that: a CSF study measuring IL-1b, TNFa and TGFb by ELISA in 19 FTD patients versus 24 matched controls, finding significantly raised CSF TNFa (0.6 vs 0.0 pg/mL, p=0.008) and TGFb (266 vs 147 pg/mL, p=0.0001) of intrathecal origin (Abstract/Results; DISCUSSION). The CONCLUSIONS state these changes 'suggest that inflammatory mechanisms are part of the pathophysiological mechanisms that lead to FTD', so the attribution is supported for FTD; the paper itself notes that its CSF changes are not specific for FTD, consistent with the citing sentence's broader 'neurodegenerative dementias' framing. (LLM, conf=0.90)
- Not matchedcites Miller et al., 2013, 2016
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Supporting our use of 18F-AV-1451 as a marker of non-amyloid-β protein aggregation, previous post-mortem work has demonstrated some binding to FTLD pathologies, albeit at a lower magnitude than that seen with Alzheimer’s pathology (Marquié et al., 2015; Lowe et al., 2016; Mcmillan et al., 2016; Sander et al., 2016).”
§ Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum > Discussion
What the sources say
- Partly supportedcites Marquié et al., 2015 sourceExperimental — accuracy not yet measured
The Results ([H-3]-AV-1451 binding assays; page unavailable) report lower binding in non-AD tauopathy and TDP-43-containing brain tissue than in AD tissue. But the autoradiography Results found no detectable binding to the FTLD lesions themselves; incidental binding in non-AD cases was associated with age-related PHF tangles. Tissue-level binding therefore does not demonstrate binding to FTLD pathologies. (LLM, conf=0.84)
- Supportedcites Lowe et al., 2016 source
The Results report absent or minimal binding in several non-Alzheimer’s tauopathies, with minimal binding observed in some cases. The Discussion states that AV-1451 preferentially binds Alzheimer’s-type tau pathology and that binding in non-Alzheimer’s primary tauopathies and TDP-43 proteinopathies is absent or minimal. This supports the claim’s qualified comparison, not binding in every FTLD case. (LLM, conf=0.90)
- Partly supportedcites Mcmillan et al., 2016 sourceExperimental — accuracy not yet measured
The paper’s opening discussion of prior autoradiography reports minimal but present 18F-AV-1451 binding to 4Rtau in corticobasal degeneration, while noting that other post-mortem studies found no cortical binding. It does not establish the claimed lower magnitude relative to Alzheimer’s pathology; its concluding discussion says direct comparisons between CBD and AD are still needed. Page numbers are not supplied in our copy. (LLM, conf=0.84)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, the situation in FTD is more complex due in part to pathological heterogeneity and the differential affinity for tau aggregates arising from different isoforms and with different ultrastructure (Jones et al., 2018).”
§ Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum > Discussion
What the sources say
- Supportedcites Jones et al., 2018 source
The Conclusions describe heterogeneous tau pathology in MAPT mutations, including aggregates with different isoform compositions and filament structures. The Discussion reports different AV-1451 signals for predominantly 4R versus mixed 3R/4R pathology and links paired helical filaments to distinct binding properties. The Results also note FTD cases not expected to have tau pathology. (LLM, conf=0.91)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Moreover, the presymptomatic dissociation of 11C-PK-11195 and 18F-AV-1451 binding (Bevan-Jones et al., 2019) argues strongly against simple cross-affinity.”
§ Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum > Discussion
What the sources say
- Supportedcites Bevan-Jones et al., 2019 source
The Methods describe a presymptomatic MAPT mutation carrier scanned with both tracers. The Results report elevated [11C]PK‐11195 binding in several regions but no region with elevated [18F]AV‐1451 binding after correction, supporting the cited dissociation. The inference about cross-affinity is the citing authors’ interpretation, not an assertion attributed to this paper. (LLM, conf=0.91)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
60 more claims · 1 with their cited sources checked
Create a free account to see all 131 claims and to verify the 3 references still open.
- Probably not a substantial claim. 23
- It may state two separate claims as one. 51
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This, together with declining immune cell function and immunosenescence, promotes a state of elevated systemic inflammation termed “inflammaging” [39, 40, 118], contributing to the functional decline in the intestine and CNS in old age [10, 13, 48].”
From Fecal microbiota transfer between young and aged mice reverses hallmarks of the aging gut, eye, and brain (2022) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Loss of intestinal barrier integrity and elevated circulating pro-inflammatory cytokine concentrations are linked with the polarization of CNS microglia toward a pro-inflammatory phenotype [11, 73, 109] and promote neurodegenerative disease [10, 13, 48].”
From Fecal microbiota transfer between young and aged mice reverses hallmarks of the aging gut, eye, and brain (2022) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This co-localization resembles that observed between protein aggregation and microglial activation in both Tau- and TDP43-associated forms of frontotemporal lobar degeneration observed by post mortem immunohistochemistry and in vivo with the ligands used in this PET study7.”
From Neuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy (2020) · cites this paper as [7]
In the citing paper
“In the related condition of frontotemporal dementia, tau burden and microglial activation are macroscopically co-localized7.”
From Neuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy (2020) · cites this paper as [7]
In the citing paper
“This finding aligns with in vivo correlation between neuroinflammation and tau aggregation in AD and frontotemporal dementia7,40.”
From Neuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy (2020) · cites this paper as [7]
Statistics recomputed
Every reported test result, recomputed from its test statistic and degrees of freedom. A result shows as not adding up only once an independent check has confirmed it.
- ConsistentF(37.4, 423.5) = 3.54reported p < .001 · recomputed p < .001
“F(37.4,423.5) = 3.54, p < .001”
- ConsistentF(33.6, 403.6) = 3.8reported p < .001 · recomputed p < .001
“F(33.6,403.6) = 3.80, p < .001”
- ConsistentF(2, 3) = 8.26reported p = .06 · recomputed p = .060
“F(2,3) = 8.26, p = .060”
- ConsistentF(5.3, 7.8) = 1.47reported p = .3 · recomputed p = .299
“F(5.3,7.8) = 1.47, p = .300”
- ConsistentF(2, 4) = 0.85reported p = .492 · recomputed p = .492
“F(2,4) = 0.85, p = .492”
63 more recomputed tests
Create a free account to see every test the Stats check recomputed.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Citations
Cites
Neurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Classification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141
Self-citationRepresentational similarity analysis-connecting the branches of systems neuroscience
Kriegeskorte, N. (2008) · Frontiers in Systems Neuroscience · doi:10.3389/neuro.06.004.2008 · Cited by 3,355
Appelhof, B., Bakker, C., Van Duinen-van den Ijssel, J. C. L., Zwijsen, S. A., Smalbrugge, M., Verhey, F. R. J., de Vugt, M. E., Zuidema, S. U., & Koopmans, R. T. C. M. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477087 · Cited by 2,760
Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.010 · Cited by 2,208
Qualitative Assessment of Verbal Fluency Performance in Frontotemporal Dementia
van den Berg, E., Jiskoot, L. C., Grosveld, M. J. H., van Swieten, J. C., & Papma, J. M. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477538 · Cited by 2,046
Innate immune activation in neurodegenerative disease
Heneka, M. T., Kummer, M. P., & Latz, E. (2014) · Nature Reviews Immunology · doi:10.1038/nri3705 · Cited by 1,437
Microglia development and function
Nayak, D., Roth, T. L., & McGavern, D. B. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120240 · Cited by 1,154
Mackenzie, I. R. A., Neumann, M., Bigio, E. H., Cairns, N. J., Alafuzoff, I., Kril, J., Kovacs, G. G., Ghetti, B., Halliday, G., Holm, I. E., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0612-2 · Cited by 1,012
Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F18]-T808
Chien, D. T., Szardenings, A. K., Bahri, S., Walsh, J. C., Mu, F., Xia, C., Shankle, W. R., Lerner, A. J., Su, M.-Y., Elizarov, A., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130098 · Cited by 675
Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807
Chien, D. T., Bahri, S., Szardenings, A. K., Walsh, J. C., Mu, F., Su, M.-Y., Shankle, W. R., Elizarov, A., & Kolb, H. C. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122059 · Cited by 651 · cited 1×
“(18)F-AV-1451 was originally developed to bind to paired helical filament tau in Alzheimer’s disease (Zhang et al., 2012; Chien et al., 2013; Xia et al., 2013), and has been extensively used in Alzheimer’s and non-Alzheimer’s diseases.”
MethodRegulation of Tau Pathology by the Microglial Fractalkine Receptor
Bhaskar, K., Konerth, M., Kokiko-Cochran, O. N., Cardona, A., Ransohoff, R. M., & Lamb, B. T. (2010) · Neuron · doi:10.1016/j.neuron.2010.08.023 · Cited by 639 · cited 1×
“, 2007) and pro-inflammatory molecules increase tau hyperphosphorylation and aggregation (Bhaskar et al., 2010).”
BackgroundMarquié, M., Normandin, M. D., Vanderburg, C. R., Costantino, I. M., Bien, E. A., Rycyna, L. G., Klunk, W. E., Mathis, C. A., Ikonomovic, M. D., Debnath, M. L., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24517 · Cited by 615
Clinical, genetic and pathological heterogeneity of frontotemporal dementia: A review
Seelaar, H., Rohrer, J. D., Pijnenburg, Y. A. L., Fox, N. C., & van Swieten, J. C. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.212225 · Cited by 609
[ 18 F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease
Xia, C., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L. F., Kasi, D., Lam, C., Liang, Q., Liu, C., Mocharla, V. P., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.008 · Cited by 605
C9orf72 is required for proper macrophage and microglial function in mice
O’Rourke, J. G., Bogdanik, L., Yáñez, A., Lall, D., Wolf, A. J., Muhammad, A. K. M. G., Ho, R., Carmona, S., Vit, J. P., Zarrow, J., et al. (2016) · Science · doi:10.1126/science.aaf1064 · Cited by 550
Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice
Yin, F., Banerjee, R., Thomas, B., Zhou, P., Qian, L., Jia, T., Ma, X., Ma, Y., Iadecola, C., Beal, M. F., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091568 · Cited by 480 · cited 1×
“Furthermore, mutations leading to haplo-insufficiency of GRN, a growth factor that has peripheral immune and central microglial regulatory functions (Petkau et al., 2010; Yin et al., 2010; Pickford et al., 2011), produce FTD syndromes characterized by TDP-43 pathology.”
BackgroundAn autoradiographic evaluation of AV-1451 Tau PET in dementia
Lowe, V. J., Curran, G., Fang, P., Liesinger, A. M., Josephs, K. A., Parisi, J. E., Kantarci, K., Boeve, B. F., Pandey, M. K., Bruinsma, T., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0315-6 · Cited by 474
Elusive roles for reactive astrocytes in neurodegenerative diseases
Ben Haim, L., Carrillo-de Sauvage, M.-A., Ceyzériat, K., & Escartin, C. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00278 · Cited by 453
Visualising microglial activation in vivo
Banati, R. B. (2002) · Glia · doi:10.1002/glia.10144 · Cited by 428
Typical and atypical pathology in primary progressive aphasia variants
Spinelli, E. G., Mandelli, M. L., Miller, Z. A., Santos‐Santos, M. A., Wilson, S. M., Agosta, F., Grinberg, L. T., Huang, E. J., Trojanowski, J. Q., Meyer, M., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24885 · Cited by 409
Rayaprolu, S., Mullen, B., Baker, M., Lynch, T., Finger, E., Seeley, W. W., Hatanpaa, K. J., Lomen-Hoerth, C., Kertesz, A., Bigio, E. H., et al. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-19 · Cited by 404
Guerreiro, R. J., Lohmann, E., Brás, J. M., Gibbs, J. R., Rohrer, J. D., Gurunlian, N., Dursun, B., Bilgic, B., Hanagasi, H., Gurvit, H., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.579 · Cited by 374 · cited 3×
“…across the FTD spectrum, corroborating suggestions from epidemiological (Lant et al., 2014; Venneti et al., 2008), genetic (Broce et al., 2018; Guerreiro et al., 2013; Rayaprolu et al., 2013), imaging (Cagnin, Rossor, Sampson, MacKinnon, & Banati, 2004; Miyoshi et al., 2010) and animal…”
BackgroundMicroglia: activation and their significance in the central nervous system
Nakajima, K., & Kohsaka, S. (2001) · Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a002969 · Cited by 371
Disparate roles of zinc in chemical hypoxia-induced neuronal death
Kim, S., Seo, J.-W., Oh, S. B., Kim, S. H., Kim, I., Suh, N., & Lee, J.-Y. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00001 · Cited by 362
Reference and target region modeling of [11C]-(R)-PK11195 brain studies.
Turkheimer, F., Edison, P., Pavese, N., Roncaroli, F., Anderson, A. N., Hammers, A., Gerhard, A., Hinz, R., Tai, Y., & Brooks, D. J. (2007) · Research Portal (King's College London) · Cited by 345
Microglial Dynamics and Role in the Healthy and Diseased Brain: A Paradigm of Functional Plasticity
Gomez-Nicola, D., & Perry, V. H. (2015) · The Neuroscientist · doi:10.1177/1073858414530512 · Cited by 340
Microglia, Amyloid, and Glucose Metabolism in Parkinson’s Disease with and without Dementia
Edison, P., Ahmed, I., Fan, Z., Hinz, R., Gelosa, G., Ray Chaudhuri, K., Walker, Z., Turkheimer, F. E., & Brooks, D. J. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.255 · Cited by 274
Microglial activation correlates in vivo with both tau and amyloid in Alzheimer’s disease
Dani, M., Wood, M., Mizoguchi, R., Fan, Z., Walker, Z., Morgan, R., Hinz, R., Biju, M., Kuruvilla, T., Brooks, D. J., et al. (2018) · Brain · doi:10.1093/brain/awy188 · Cited by 270 · cited 2×
“correlated with tau aggregation (Dani et al., 2018), and Figure 5 Immunohistochemistry from cases with FTLD-TDP43 types A and C, FTLD-P (Pick’s disease), and Alzheimer’s”
BackgroundMethodAnatomy of Language Impairments in Primary Progressive Aphasia
Rogalski, E., Cobia, D., Harrison, T. M., Wieneke, C., Thompson, C. K., Weintraub, S., & Mesulam, M.-M. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5544-10.2011 · Cited by 208
A highly selective and specific PET tracer for imaging of tau pathologies
Zhang, W., Arteaga, J., Cashion, D. K., Chen, G., Gangadharmath, U., Gomez, L. F., Kasi, D., Lam, C., Liang, Q., Liu, C., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120712 · Cited by 195
Sander, K., Lashley, T., Gami, P., Gendron, T., Lythgoe, M. F., Rohrer, J. D., Schott, J. M., Revesz, T., Fox, N. C., & Årstad, E. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.01.003 · Cited by 187
In vivo detection of microglial activation in frontotemporal dementia
Cagnin, A., Rossor, M., Sampson, E. L., MacKinnon, T., & Banati, R. B. (2004) · Annals of Neurology · doi:10.1002/ana.20332 · Cited by 187 · cited 2×
“In vivo PET studies in small samples have shown that neuroinflammation anticipates atrophy in clinically established FTD (Cagnin et al., 2004) and precedes both symptoms and the detectability of tau aggregation by PET in MAPT mutation carriers (Miyoshi et al.”
BackgroundBroce, I., Karch, C. M., Wen, N., Fan, C. C., Wang, Y., Hong Tan, C., Kouri, N., Ross, O. A., Höglinger, G. U., Muller, U., et al. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002487 · Cited by 183
Recollection- and familiarity-based decisions reflect memory strength
Wiesmann, M. (2008) · Frontiers in Systems Neuroscience · doi:10.3389/neuro.06.001.2008 · Cited by 175
Yaqub, M. M., van Berckel, B. N. M., Schuitemaker, A., Hinz, R., Turkheimer, F., Tomasi, G., Lammertsma, A. A., & Boellaard, R. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.59 · Cited by 172
TDP-43 frontotemporal lobar degeneration and autoimmune disease
Miller, Z. A., Rankin, K. P., Graff-Radford, N. R., Takada, L. T., Sturm, V. E., Cleveland, C. M., Criswell, L. A., Jaeger, P. A., Stan, T., Heggeli, K. A., et al. (2013) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-304644 · Cited by 170
18 F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers
Smith, R., Puschmann, A., Schöll, M., Ohlsson, T., van Swieten, J., Honer, M., Englund, E., & Hansson, O. (2016) · Brain · doi:10.1093/brain/aww163 · Cited by 168 · cited 1×
“…resulting from MAPT mutations, showing binding in areas typically affected in FTD and affected at post mortem (W. Richard Bevan-Jones et al., 2016; Smith et al., 2016), and by the elevated binding in the affected brain regions of patients with svPPA (William Richard Bevan-Jones et al., 2017;…”
BackgroundProgranulin expression in the developing and adult murine brain
Petkau, T. L., Neal, S. J., Orban, P. C., MacDonald, J. L., Hill, A. M., Lu, G., Feldman, H. H., Mackenzie, I. R. A., & Leavitt, B. R. (2010) · Journal of Comparative Neurology · doi:10.1002/cne.22430 · Cited by 152
Giraldo, M., Lopera, F., Siniard, A. L., Corneveaux, J. J., Schrauwen, I., Carvajal, J., Muñoz, C., Ramirez-Restrepo, M., Gaiteri, C., Myers, A. J., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.02.016 · Cited by 147
Vermeiren, C., Motte, P., Viot, D., Mairet‐Coello, G., Courade, J., Citron, M., Mercier, J., Hannestad, J., & Gillard, M. (2018) · Movement Disorders · doi:10.1002/mds.27271 · Cited by 143
Buetti, N., Atkinson, A., Marschall, J., & Kronenberg, A. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013665 · Cited by 134
The Role of Neuroinflammation in Dementias
Pasqualetti, G., Brooks, D. J., & Edison, P. (2015) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-015-0531-7 · Cited by 133
Baker, S. L., Harrison, T. M., Maass, A., La Joie, R., & Jagust, W. J. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.224113 · Cited by 132
Venneti, S., Wang, G., Nguyen, J., & Wiley, C. A. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318188b204 · Cited by 129
Sjogren, M. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.019422 · Cited by 125
In vivo retention of 18 F-AV-1451 in corticobasal syndrome
Smith, R., Schöll, M., Widner, H., van Westen, D., Svenningsson, P., Hägerström, D., Ohlsson, T., Jögi, J., Nilsson, C., & Hansson, O. (2017) · Neurology · doi:10.1212/wnl.0000000000004264 · Cited by 117
[ 11 C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy
Passamonti, L., Rodríguez, P. V., Hong, Y. T., Allinson, K. S. J., Bevan-Jones, W. R., Williamson, D., Jones, P. S., Arnold, R., Borchert, R. J., Surendranathan, A., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005610 · Cited by 115
Self-citationImaging of neuroinflammation in dementia: a review
Stefaniak, J., & O'Brien, J. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-311336 · Cited by 109
Self-citationProgranulin is a chemoattractant for microglia and stimulates their endocytic activity
Pickford, F., Marcus, J., Camargo, L. M., Xiao, Q., Graham, D., Mo, J.-R., Burkhardt, M., Kulkarni, V., Crispino, J., Hering, H., et al. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2010.11.002 · Cited by 107
Identification of two benzodiazepine binding sites on cells cultured from rat cerebral cortex.
McCarthy, K. D., & Harden, T. K. (1981) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)32395-5 · Cited by 104
Flortaucipir tau PET imaging in semantic variant primary progressive aphasia
Makaretz, S. J., Quimby, M., Collins, J., Makris, N., McGinnis, S., Schultz, A., Vasdev, N., Johnson, K. A., & Dickerson, B. C. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316409 · Cited by 104
Patterns of microglial cell activation in frontotemporal lobar degeneration
Lant, S. B., Robinson, A. C., Thompson, J. C., Rollinson, S., Pickering‐Brown, S., Snowden, J. S., Davidson, Y. S., Gerhard, A., & Mann, D. M. A. (2014) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12092 · Cited by 102
Increased prevalence of autoimmune disease within C9 and FTD/MND cohorts: Completing the picture
Miller, Z. A., Sturm, V. E., Camsari, G. B., Karydas, A., Yokoyama, J. S., Grinberg, L. T., Boxer, A. L., Rosen, H. J., Rankin, K. P., Gorno-Tempini, M. L., et al. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000301 · Cited by 100
Plaque-associated local toxicity increases over the clinical course of Alzheimer disease
Serrano-Pozo, A., Betensky, R. A., Frosch, M. P., & Hyman, B. T. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.10.010 · Cited by 100
Moore, K. J., Candy, B., Davis, S., Gola, A., Harrington, J., Kupeli, N., Vickerstaff, V., King, M., Leavey, G., Nazareth, I., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-015515 · Cited by 93
McMillan, C. T., Irwin, D. J., Nasrallah, I., Phillips, J. S., Spindler, M., Rascovsky, K., Ternes, K., Jester, C., Wolk, D. A., Kwong, L. K., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1640-3 · Cited by 87
Bevan-Jones, W. R., Cope, T. E., Jones, P. S., Passamonti, L., Hong, Y. T., Fryer, T. D., Arnold, R., Allinson, K. S. J., Coles, J. P., Aigbirhio, F. I., et al. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316402 · Cited by 84
Self-citationVarley, J., Brooks, D. J., & Edison, P. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.08.105 · Cited by 82
Translational neuroimaging: positron emission tomography studies of monoamine oxidase
Fowler, J. S., Logan, J., Volkow, N. D., & Wang, G.-J. (2005) · Molecular Imaging and Biology · doi:10.1007/s11307-005-0016-1 · Cited by 81 · cited 2×
“Although 18F-AV-1451 has weak affinity for both types of MAO (Drake et al., 2019), selective blockade of MAOA and MAOB leads to only minor changes in the estimated cortical binding from PET in nonhuman primates (Drake et al., 2019), while clinical treatment with MAO inhibitors does not significantly change estimated 1…”
BackgroundMiyoshi, M., Shinotoh, H., Wszolek, Z. K., Strongosky, A. J., Shimada, H., Arakawa, R., Higuchi, M., Ikoma, Y., Yasuno, F., Fukushi, K., et al. (2010) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2010.04.004 · Cited by 75
Bevan-Jones, W. R., Surendranathan, A., Passamonti, L., Vázquez Rodríguez, P., Arnold, R., Mak, E., Su, L., Coles, J. P., Fryer, T. D., Hong, Y. T., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013187 · Cited by 75
Self-citation18F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies
Smith, R., Schöll, M., Londos, E., Ohlsson, T., & Hansson, O. (2018) · Scientific Reports · doi:10.1038/s41598-018-23041-x · Cited by 74
In vivo 18 F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms
Jones, D. T., Knopman, D. S., Graff-Radford, J., Syrjanen, J. A., Senjem, M. L., Schwarz, C. G., Dheel, C., Wszolek, Z., Rademakers, R., Kantarci, K., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005117 · Cited by 71 · cited 11×
“…PET studies in small samples have shown that neuroinflammation anticipates atrophy in clinically established FTD (Cagnin et al., 2004) and precedes both symptoms and the detectability of tau aggregation by PET in MAPT mutation carriers (W Richard Bevan-Jones et al., 2018; Miyoshi et al., 2010).”
BackgroundInfluentialMapping neuroinflammation in frontotemporal dementia with molecular PET imaging
Zhang, J. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0236-5 · Cited by 62
Woollacott, I. O. C., Nicholas, J. M., Heslegrave, A., Heller, C., Foiani, M. S., Dick, K. M., Russell, L. L., Paterson, R. W., Keshavan, A., Fox, N. C., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0405-8 · Cited by 62
MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([18F]-AV-1451) Binding
Hansen, A. K., Brooks, D. J., & Borghammer, P. (2018) · Molecular Imaging and Biology · doi:10.1007/s11307-017-1143-1 · Cited by 51
Identification of AV-1451 as a Weak, Nonselective Inhibitor of Monoamine Oxidase
Drake, L. R., Pham, J. M., Desmond, T. J., Mossine, A. V., Lee, S. J., Kilbourn, M. R., Koeppe, R. A., Brooks, A. F., & Scott, P. J. H. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00326 · Cited by 51
[18F]AV‐1451 PET in behavioral variant frontotemporal dementia due to MAPT mutation
Bevan Jones, W. R., Cope, T. E., Passamonti, L., Fryer, T. D., Hong, Y. T., Aigbirhio, F., Kril, J. J., Forrest, S. L., Allinson, K., Coles, J. P., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.366 · Cited by 44
Self-citationIn vivo evidence for pre‐symptomatic neuroinflammation in a MAPT mutation carrier
Bevan‐Jones, W. R., Cope, T. E., Jones, P. S., Passamonti, L., Hong, Y. T., Fryer, T., Arnold, R., Coles, J. P., Aigbirhio, F. I., O'Brien, J. T., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.683 · Cited by 36
Self-citation[ 18 F]AV‐1451 binding is increased in frontotemporal dementia due to C9orf72 expansion
Bevan‐Jones, R. W., Cope, T. E., Jones, S. P., Passamonti, L., Hong, Y. T., Fryer, T., Arnold, R., Coles, J. P., Aigbirhio, F. A., Patterson, K., et al. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.631 · Cited by 23
Self-citationA novel mechanism underlying pathogenesis of Down syndrome
Wang, X., Zhao, Y., Zhang, X., Zhou, Y., Ranscht, B., Gage, F. H., Mobley, W. C., Zhang, Y., Lipton, S. A., Hong, W., et al. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-s1-o23 · Cited by 7
Cited by
Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases
Loh, J. S., Mak, W. Q., Tan, L. K. S., Ng, C. X., Chan, H. H., Yeow, S. H., Foo, J. B., Ong, Y. S., How, C. W., & Khaw, K. Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01743-1 · Cited by 1,193
Parker, A., Romano, S., Ansorge, R., Aboelnour, A., Le Gall, G., Savva, G. M., Pontifex, M. G., Telatin, A., Baker, D., Jones, E., et al. (2022) · Microbiome · doi:10.1186/s40168-022-01243-w · Cited by 368
Tauopathies: new perspectives and challenges
Zhang, Y., Wu, K.-M., Yang, L., Dong, Q., & Yu, J.-T. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00533-z · Cited by 323
Sun, Y., Koyama, Y., & Shimada, S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.903455 · Cited by 304
PET imaging of neuroinflammation in neurological disorders
Kreisl, W. C., Kim, M.-J., Coughlin, J. M., Henter, I. D., Owen, D. R., & Innis, R. B. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30346-x · Cited by 242
Metadata
- Authors
- Bevan-Jones, W. R., Cope, T. E., Jones, P. S., Kaalund, S. S., Passamonti, L., Allinson, K., Green, O., Hong, Y. T., Fryer, T. D., Arnold, R., Coles, J. P., Aigbirhio, F. I., Larner, A. J., Patterson, K., O’Brien, J. T., & Rowe, J. B.
- Affiliations
- University of Cambridge (GB)
- MRC Cognition and Brain Sciences Unit (GB)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- Institute of Molecular Bioimaging and Physiology (IT)
- Walton Centre (GB)
- Department of Psychiatry, University of Cambridge, Cambridge, UK
- Corresponding author
- Cope, Thomas E
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-03-01
- Volume
- 143
- Issue
- 3
- Pages
- 1010-1026
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC7089669
- OpenAlex
- W3011374615
- Cited by
- 124
- References
- 79
- Citations by year
- 2026: 17 · 2025: 15 · 2024: 19 · 2023: 17 · 2022: 21 · 2021: 18 · 2020: 16
- FWCI
- 13.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Apollo (cc-by)
- Funders
- National Institute for Health Research Cambridge Biomedical Research Centre
- Cambridge Brain Bank
- Wellcome Trust (103838)
- Cambridge Centre for Parkinson-plus; the Medical Research Council (MR/P01271X/1)
- National Institute for Health Research, Association of British Neurologists
- Patrick Berthoud Charitable Trust
- Lundbeck Foundation
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- frontotemporal dementia, neuroinflammation, microglial activation, tau pathology, TDP-43 pathology, protein aggregation, 18F-AV-1451, positron emission tomography, semantic dementia, behavioral variant frontotemporal dementia
- MeSH terms
- Aged, Carbolines, Carbon Radioisotopes, DNA-Binding Proteins, Female, Humans, Inflammation, Isoquinolines, Male, Middle Aged, Protein Binding, Case-Control Studies, Microglia, Tauopathies, Positron-Emission Tomography, Frontotemporal Dementia, Protein Aggregates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.